Literature DB >> 12912974

Activation of a p53-mediated apoptotic pathway in quiescent lymphocytes after the inhibition of DNA repair by fludarabine.

V Ashutosh Rao1, William Plunkett.   

Abstract

PURPOSE: The inhibition of UV-initiated DNA repair by 9-beta-D-arabinofuranosyl-2-fluoroadenine (F-ara-A), the nucleoside of fludarabine, induces apoptosis in quiescent human lymphocytes. The sensing and signaling mechanisms after DNA repair inhibition by F-ara-A are unknown. The purpose of this study was 2-fold: (a) determine the importance of the inhibition of DNA repair processes for F-ara-A cytotoxicity and (b) identify the apoptotic signaling mechanism(s) that respond to DNA repair inhibition by F-ara-A. EXPERIMENTAL
DESIGN: Lymphocytes were treated with F-ara-A to accumulate the active triphosphate metabolite and subsequently DNA repair was activated by UV irradiation. Cell viability was quantitated with respect to the treatments alone and in combination to evaluate the actions of F-ara-A inhibition of DNA repair on p53 status and Fas death receptor ligand expression and function.
RESULTS: Preincubation of lymphocytes with 3 micro M F-ara-A inhibited DNA repair initiated by 2 J/m(2) UV and induced greater than additive apoptosis after 24 h. After equivalent repair inhibition with 0.1 micro M aphidicolin, there was apparently lesser p53 activation and significantly less apoptosis in irradiated lymphocytes than after 3 micro M F-ara-A. Blocking the incorporation of F-ara-A nucleotide into repairing DNA using 30 micro M aphidicolin lowered the apoptotic response to that observed with aphidicolin and UV. p53 serine 15 phosphorylation and protein accumulation were detected 2 h after treatment. Fas and Fas ligand mRNA expression and protein levels increased significantly after repair inhibition. Neutralizing antibodies against Fas or Fas ligand significantly reduced apoptosis.
CONCLUSIONS: These results suggest that inhibition of UV-induced DNA repair by F-ara-A is critical for cytotoxicity and that induction of apoptosis may be conducted by a p53-mediated signaling mechanism to the Fas death pathway.

Entities:  

Mesh:

Substances:

Year:  2003        PMID: 12912974

Source DB:  PubMed          Journal:  Clin Cancer Res        ISSN: 1078-0432            Impact factor:   12.531


  8 in total

1.  Killing of chronic lymphocytic leukemia by the combination of fludarabine and oxaliplatin is dependent on the activity of XPF endonuclease.

Authors:  Alma Zecevic; Deepa Sampath; Brett Ewald; Rong Chen; William Wierda; William Plunkett
Journal:  Clin Cancer Res       Date:  2011-06-01       Impact factor: 12.531

Review 2.  The role of DNA repair in chronic lymphocytic leukemia pathogenesis and chemotherapy resistance.

Authors:  Deepa Sampath; William Plunkett
Journal:  Curr Oncol Rep       Date:  2007-09       Impact factor: 5.075

3.  A phase I study of fludarabine, cytarabine, and oxaliplatin therapy in patients with relapsed or refractory acute myeloid leukemia.

Authors:  Apostolia Maria Tsimberidou; Michael J Keating; Elias J Jabbour; Farhad Ravandi-Kashani; Susan O'Brien; Elihu Estey; Neby Bekele; William K Plunkett; Hagop Kantarjian; Gautam Borthakur
Journal:  Clin Lymphoma Myeloma Leuk       Date:  2014-02-03

4.  Cladribine and Fludarabine Nucleoside Change the Levels of CD Antigens on B-Lymphoproliferative Disorders.

Authors:  Carlos Cassano; Swetlana Mactier; Stephen P Mulligan; Larissa Belov; Pauline Huang; Richard I Christopherson
Journal:  Int J Proteomics       Date:  2010-05-05

5.  Targeting DNA repair with aphidicolin sensitizes primary chronic lymphocytic leukemia cells to purine analogs.

Authors:  Eliza Starczewska; Maxime Beyaert; Lucienne Michaux; Marie-Christiane Vekemans; Pascale Saussoy; Vanesa Bol; Ainhoa Arana Echarri; Caroline Smal; Eric Van Den Neste; Françoise Bontemps
Journal:  Oncotarget       Date:  2016-06-21

6.  Nucleotide excision repair as a targetable vulnerability in leukemia.

Authors:  Gregor Lohmann; Björn Schumacher; Marco Herling
Journal:  Oncotarget       Date:  2017-12-06

7.  A phase I-II trial of fludarabine, bendamustine and rituximab (FBR) in previously treated patients with CLL.

Authors:  Nitin Jain; Kumudha Balakrishnan; Alessandra Ferrajoli; Susan M O'Brien; Jan A Burger; Tapan M Kadia; Jorge E Cortes; Mary L Ayres; Francesco Paolo Tambaro; Michael J Keating; Varsha Gandhi; William G Wierda
Journal:  Oncotarget       Date:  2017-03-28

8.  Phase I clinical trial of the base excision repair inhibitor methoxyamine in combination with fludarabine for patients with advanced hematologic malignancies.

Authors:  Paolo F Caimi; Brenda W Cooper; Basem M William; Afshin Dowlati; Paul M Barr; Pingfu Fu; John Pink; Yan Xu; Hillard M Lazarus; Marcos de Lima; Stanton L Gerson
Journal:  Oncotarget       Date:  2017-08-09
  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.